(Q33732334)

29 July 2017

1 reference

title

Respiratory syncytial virus infection (English)

1 reference

29 July 2017

0 references

E A Simoes

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

354

1 reference

29 July 2017

issue

9181

1 reference

29 July 2017

page(s)

847-852

1 reference

Recovery of cytopathogenic agent from chimpanzees with coryza

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: a computer analysis of 58,500 patients covering a period of eight years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Coordinated Data Group of BOSTID Researchers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus infection in tropical and developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for va

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Pathogenesis of respiratory syncytial virus vaccine-augmented pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Acute respiratory distress syndrome caused by respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Risk factors for respiratory syncytial virus associated apnoea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Severity of respiratory syncytial virus infection is related to virus strain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

The clinical spectrum of respiratory syncytial virus disease in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Local variability in respiratory syncytial virus disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Dexamethasone in bronchiolitis: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Vitamin A therapy for children with respiratory syncytial virus infection: a multicenter trial in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Epidemiology of Acute Respiratory Infections in Children of Developing Countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus genotypes and disease severity among children in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Distinct types of lung disease caused by functional subsets of antiviral T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Inhaled budesonide for chronic wheezing under 18 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Anti-inflammatory therapy reduces wheezing after bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2980040-3

7 January 2021

10.1016/S0140-6736(99)80040-3

Identifiers

DOI

1 reference

29 July 2017

1 reference